A new trading day began on Friday, with Y-Mabs Therapeutics Inc (NASDAQ: YMAB) stock price down -3.88% from the previous day of trading, before settling in for the closing price of $11.59. YMAB’s price has ranged from $5.04 to $20.90 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 37.03% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged -29.33%. With a float of $37.18 million, this company’s outstanding shares have now reached $43.67 million.
In an organization with 100 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 88.83%, operating margin of -33.66%, and the pretax margin is -27.28%.
Y-Mabs Therapeutics Inc (YMAB) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Y-Mabs Therapeutics Inc is 16.99%, while institutional ownership is 60.12%. The most recent insider transaction that took place on Sep 13 ’24, was worth 875,550. In this transaction CHIEF BUSINESS OFFICER of this company sold 65,000 shares at a rate of $13.47, taking the stock ownership to the 97,681 shares. Before that another transaction happened on Sep 16 ’24, when Company’s CHIEF BUSINESS OFFICER sold 30,000 for $12.97, making the entire transaction worth $389,100. This insider now owns 67,681 shares in total.
Y-Mabs Therapeutics Inc (YMAB) Performance Highlights and Predictions
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -0.02 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.12 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -29.33% per share during the next fiscal year.
Y-Mabs Therapeutics Inc (NASDAQ: YMAB) Trading Performance Indicators
Here are Y-Mabs Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.54. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.67.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.54, a number that is poised to hit -0.11 in the next quarter and is forecasted to reach -0.54 in one year’s time.
Technical Analysis of Y-Mabs Therapeutics Inc (YMAB)
Let’s dig in a bit further. During the last 5-days, its volume was 0.37 million. That was better than the volume of 0.33 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 10.51%. Additionally, its Average True Range was 0.97.
During the past 100 days, Y-Mabs Therapeutics Inc’s (YMAB) raw stochastic average was set at 35.45%, which indicates a significant increase from 9.96% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 73.84% in the past 14 days, which was higher than the 65.46% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $13.98, while its 200-day Moving Average is $13.81. However, in the short run, Y-Mabs Therapeutics Inc’s stock first resistance to watch stands at $11.67. Second resistance stands at $12.19. The third major resistance level sits at $12.73. If the price goes on to break the first support level at $10.60, it is likely to go to the next support level at $10.06. Assuming the price breaks the second support level, the third support level stands at $9.54.
Y-Mabs Therapeutics Inc (NASDAQ: YMAB) Key Stats
With a market capitalization of 479.58 million, the company has a total of 44,789K Shares Outstanding. Currently, annual sales are 84,820 K while annual income is -21,430 K. The company’s previous quarter sales were 18,460 K while its latest quarter income was -7,000 K.
